Early treatment of Parkinson’s disease: how and when should therapy be initiated?
Hauser, RA. 2007. “Early Treatment of Parkinson’s Disease: How and When Should Therapy Be Initiated?”. Therapeutic Spotlight.
Search
Search results
373 results found
Long-term efficacy of rasagiline in early Parkinson's disease.
Lew, MF, RA Hauser, HI Hurtig, WG Ondo, J Wojcieszek, T Goren, and CJ Fitzer-Attas. 2010. “Long-Term Efficacy of Rasagiline in Early Parkinson’s Disease.”. Int J Neurosci.
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser, RA, AH Shapira, O Rascol, P Barone, Y Mizuno, L Salin, M Haaksma, N Juhel, and W Poewe. 2010. “Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson’s Disease.”. Mov Disord.
Treatment of early Parkinson's disease. Part 1.
Simuni, T, KE Lyons, R Pahwa, RA Hauser, C Comella, L Elmer, and D Weintraub. 2009. “Treatment of Early Parkinson’s Disease. Part 1.”. Eur Neurol.
Levodopa: past, present, and future
Hauser, RA. 2009. “Levodopa: Past, Present, and Future”. Eur Neurol.
A pilot, double-blind, placebo-controlled trial of pregabalin (lyrica) in the treatment of essential tremor.
Zesiewicz, TA, CL Ward, RA Hauser, JL Salemi, S Siraj, MC Wilson, and KL Sullivan. 2007. “A Pilot, Double-Blind, Placebo-Controlled Trial of Pregabalin (lyrica) in the Treatment of Essential Tremor.”. Mov Disord.
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
Group, Parkinson Study, and RA Hauser. 2007. “Mixed Lineage Kinase Inhibitor CEP-1347 Fails to Delay Disability in Early Parkinson Disease.”. Neurology.
End-of-dose wearing off in Parkinson disease: a 9-question survey assessment.
Stacy, M, RA Hauser, W Oertel, A Shapira, K Sethi, F Stocchi, and E Tolosa. 2006. “End-of-Dose Wearing off in Parkinson Disease: A 9-Question Survey Assessment.”. Clin Neuropharmacol.
Levetiracetam-Induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol 2005;28:188-190.
Zesiewicz, TA, J Sanchez-Ramos, KL Sullivan, and RA Hauser. 2005. “Levetiracetam-Induced Parkinsonism in a Huntington Disease Patient. Clin Neuropharmacol 2005;28:188-190.”. Clin Neuropharmacol.
Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord 2005;11:469-471.
Sullivan, KL, RA Hauser, ED Louis, G Chari, and TA Zesiewicz. 2005. “Levetiracetam for the Treatment of Generalized Dystonia. Parkinsonism Relat Disord 2005;11:469-471.”. Parkinsonism Relat Disord.